AUA Guidelines: Evaluation and Management of Localized Renal Masses: A Case-Based Approach Webcast (2020)

This course will be interactive and case-based with imaging and videos that will lead into discussion of the most important AUA Guidelines recommendations. A primary focus will be surgical management and efforts to reduce the risk of complications, manage intraoperative complications, or optimize oncologic and functional outcomes. We will each take 3-5 minutes to highlight one recent major development in the field of kidney cancer.


Support provided by independent educational grants from:

  • Astellas
  • AstraZeneca
  • Bristol-Myers Squibb
  • Genentech
  • Merck
  • Pfizer, Inc.
  • Sanofi Genzyme

Target Audience

  • Urologists
  • Residents
  • Advanced Practice Providers (Nurse Practitioners & Physician Assistants)

Learning Objectives

After completing this activity, participants will be able to:

  1. Surgically manage challenging kidney cancer cases to prevent complications and optimize functional and oncologic outcomes.
  2. Evaluate, diagnose, and risk stratify patients with localized renal masses.
  3. Counsel patients with localized renal masses about the various management strategies, including oncologic and functional considerations and potential morbidities.
  4. Manage patients with localized renal masses, including appropriate and safe utilization of PN, RN, ablation and active surveillance.
  5. Apply the AUA Guidelines regarding the evaluation and management of localized renal masses safely and effectively and apply recent data about kidney cancer from 2019-2020 to clinical practice.
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Course opens: 
Course expires: 

Education Council Disclosures

PDF icon Education Council Disclosures

AUA Office of Education Staff has nothing to disclose.

Course Director(s)

Steven Campbell, MD, PHD

has no relevant financial relationships to disclose at this time.

Brian Lane, MD, PhD, FACS

has no relevant financial relationships to disclose at this time.

Phillip Pierorazio, MD

has a financial relationship (Independent contractor) with Urogen Pharmaceuticals;.
has a financial relationship (Independent contractor) with Ethicon (J&J);.
has a financial relationship (Independent contractor) with Wolters Kluwer;.

Robert Uzzo, MD,CEO,MBA

has a financial relationship (Other) with Janssen;.
has a financial relationship (Independent contractor) with UroGen Pharma;.
has a financial relationship (Independent contractor) with Amgen;.


Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 1.50 hours

Release Date: August, 2020
Expiration Date: August, 2021


The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


The American Urological Association designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.


It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.


All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.


All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty


The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Please login or register to take this course.